Ang-2 serum levels did not differ significantly after the third cycle of treatment compared with serum levels at admission in NSCLC and SCLC patients who received platinum-based chemotherapy (p = ns, Figure 5B) [17,18]. This evidence concerns the gene ANGPT2 and small cell lung carcinoma.